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Preeclampsia is a multisystemic pregnancy disorder and a major cause of maternal and neonatal morbidity and mortality
worldwide. The exact pathophysiology of preeclampsia remains unclear; however, it is speculated that the various pathologies
can be attributed to impaired vascular remodelling and elevated oxidative stress within the placenta. Oxidative stress plays a key
role in cell ageing, and the persistent presence of elevated oxidative stress precipitates cellular senescence and mitochondrial
dysfunction, resulting in premature ageing of the placenta. Premature ageing of the placenta is associated with placental
insufficiency, which reduces the functional capacity of this critical organ and leads to abnormal pregnancy outcomes. The
changes brought about by oxidative insults are irreversible and often lead to deleterious modifications in macromolecules such
as lipids and proteins, DNA mutations, and alteration of mitochondrial functioning and dynamics. In this review, we have
summarized the current knowledge of placental ageing in the aetiology of adverse pregnancy outcomes and discussed the
hallmarks of ageing which could be potential markers for preeclampsia and fetal growth restriction.
1. Introduction
Preeclampsia can be defined as de novo hypertension after
20 weeks of gestation in the presence of proteinuria and
maternal organ/uteroplacental dysfunction [1]. It is one
of the leading causes of maternal and neonatal morbidity
and mortality affecting about 3 to 8% of pregnancies world-
wide [2]. Preterm birth as a result of iatrogenic delivery
is a common factor in preeclampsia with up to 25% of
babies born to preeclamptic mothers being growth restricted
[2, 3]. Preeclampsia and IUGR are pregnancy-specific disor-
ders that are associated with placental insufficiency [4].
Complications associated with preeclampsia are responsi-
ble for about 15% of maternal deaths and high perinatal
mortality rates worldwide [5]. Ageing is experienced inev-
itably by organs; however, in preeclampsia, the presence
of persistent oxidative stress accelerates this process
resulting in premature ageing of the placenta [6]. It has
been reported by various studies that premature placental
ageing is associated with telomere shortening, cellular
senescence, and mitochondrial dysfunction [7–10].
2. Physiology of Ageing
Ageing is a unidirectional phenomenon experienced inevita-
bly by every tissue. It can be characterised as cellular senes-
cence through decline in functionality and mitochondrial
dysfunction through altered metabolism and signalling.
2.1. Cellular Senescence. Cells are capable of replication,
dividing into two exact copies of the parent cell. This includes
division of the genetic material by unwinding and splitting of
the DNA strands, in order to form two new copies as daugh-
ter strands. Telomeres are cap-like nucleotide repeats (TTAG
GG) present on the end of each strand. Damage to DNA
strands activates signalling cascades (ataxia telangiectasia-
mutated (ATM) and ataxia telangiectasia and Rad3-related
(ATR) pathways) that arrest cell division, induce cellular
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senescence, and promote cell death [11]. Telomeres with
other proteins like shelterin protect the end of nuclei from
being recognised as a double-strand damaged region (DDR)
[11]. It has been shown that telomeres shorten after every
replication cycle [12]. With the increase in proliferation
and decrease in telomere size, cells enter senescence or a
growth retardation phase (Hayflick limit) which ultimately
results in cellular death [12]. Telomere shortening has been
associated with various genetic diseases such as progeria or
premature ageing and Hutchinson-Gilford syndrome [13].
In some cases, such as cancer, cells can bypass senescence
and keep proliferating, becoming immortal. However, even
cancer cells do not divide indefinitely, and they enter a crisis
stage which results in either cellular death or telomere length
stabilization with a consequent upregulation of the telome-
rase enzyme to maintain telomere length [14]. Telomerase is
a RNA-protein complex that replenishes the lost nucleotides
to preserve the length of the telomere [15]. In somatic cells,
telomerases are turned off as a protective mechanism to pre-
vent neoplastic changes [16], but their activity is more pro-
nounced in germ cells, stem cells, and 90% of cancer cells [17].
2.2. Mitochondrial Dysfunction. Mitochondria are key regu-
lators of metabolism, redox balance, and apoptosis. During
the electron transport chain (ETC), electrons are pumped
across the inner mitochondrial membrane (from reduced
compounds to molecular oxygen) to create an efflux for
synthesis of energy [18]. According to the free radical or
oxidative stress hypothesis of ageing, there are a number
of timeline events occurring during oxidative phosphoryla-
tion resulting in leaching of electrons from mitochondrial
membranes which reacts with oxygen, forming free radi-
cals such as superoxide, ultimately impairing redox bal-
ance [19, 20]. The free radical theory has been succeeded
by the damage theory hypothesis which suggests that ageing
can be associated with the frequent and inevitable cumulative
damage at a molecular level caused by accumulated reactive
oxygen species (ROS) and its by-products and enzymes
[21]. Accumulated reactive oxygen species (ROS) leads to
reversible and irreversible changes within cells, resulting in
loss of molecular functioning and increased oxidative stress,
a phenomenon frequently associated with senescence, as
shown in Figure 1 [19, 20].
Mitochondrial functioning in ageing has been studied
extensively; it has been reported by a number of articles
that mitochondrial density, respiratory capacity, and ATP
production decline with cellular ageing [22–24]. Apart
from reduced functionality, ageing is accompanied with
damaged mitochondrial DNA (mtDNA), mutations, and
mitophagy [22, 25].
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Figure 1: Cause and consequence of placental ageing: the pathophysiology of placental conditions such as preeclampsia and fetal growth
restriction is often associated with internal and external factors such as oxidative stress, genetic, immunological, and environmental. This
can result in placental insufficiency with further evidence of premature ageing of the placenta as a consequence of cellular senescence and
mitochondrial dysfunction [130, 131].
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Impaired redox signalling induces various modifications
within the macromolecules and mutations within mtDNA;
however, deleterious effects of these mtDNA mutations are
still not fully elucidated [26–28]. The bottleneck effect, which
explains genetic drifts and variations in small population
subsets, as is the case with mtDNA mutations, may transmit
small variations in germlines which are amplified in later
stages of oogenesis [29, 30]. A few studies have reported that
mutations in yeast mtDNA result in a shorter lifespan when
mitophagy is inhibited [31, 32]. Reduced mtDNA copy num-
bers have been associated with ageing and associated diseases
including cardiovascular disease (cardiomyopathy, athero-
sclerosis), neurodegenerative disease (Alzheimer’s disease,
Parkinson’s disease), cancer, and premature ageing of ovaries
in women [33, 34].
Mitophagy is a protective mechanism to maintain mito-
chondrial quality, remove mutated mtDNA, and ensure
mitochondrial homeostasis [35]. Furthermore, mitochon-
drial dynamics are maintained through frequent mitochon-
drial fission and fusion [36]. Oxidative damage to the
mitochondria can cause impaired fission with asymmetric
membrane potentials of daughter mitochondria which fail
to fuse effectively, resulting in accumulated malformed mito-
chondrial proteins with decreased autophagic capacity [37].
Palikaras et al. showed that mitophagy is required for longev-
ity in C. elegans as a result of reduced insulin/IGF-1 signal-
ling or impaired mitochondrial function [38].
Furthermore, loss of mitochondrial biogenesis through
an imbalance of mitophagy and mitochondrial fission/fusion
and accumulation of mitochondrial debris leads to cardiac
ageing in mice [39, 40].
Impaired mitochondrial functioning is reflective of the
mitochondrial unfolded protein response (UPRmt) [41]
which is regulated by communication between mitochon-
drial and nuclear proteins, where nuclear remodelling is
required for the activation of UPRmt [42]. When stress is
induced within cells, UPRmt is upregulated to promote
repairs, but in cases of prolonged UPRmt action, mutations
may be induced within the mtDNA [42]. Experiments on
C. elegans have shown that UPRmt upregulation and imbal-
ance in mitonuclear response induce longevity [43, 44].
Cell senescence is a result of nuclear damage usually
associated with high oxidative stress and accumulation of
ROS, debris, or misfolded proteins. Innate immune medi-
ators with Senescence-Associated Secretory Phenotypes
(SASPs) including cytokines, chemokines, growth factors,
and proteases are responsible for clearing debris from dead
or dying cells which might activate proapoptotic p53 and
AKT signalling pathways [45–47]. In several studies,
removal of inflammatory mediators and consequent sig-
nalling caused a reversal in cellular ageing, indicating that
inflammation might be both cause and consequence in cel-
lular senescence [48–50].
3. Pathophysiology of Preeclampsia
The pathophysiology of preeclampsia, even after decades of
research, is not completely understood. Preeclampsia can be
characterised as early onset, comprising or less than 20% of
all cases, or late onset, comprising the remaining 80% [51].
Several hypotheses have been proposed to fully elucidate
the underlying pathological mechanisms [51–54]. The pla-
cental origin of preeclampsia hypothesis describes inefficient
trophoblast invasion and remodelling of maternal spiral
arteries, causing “placental syndrome,” subsequently result-
ing in preeclampsia and fetal growth restriction [51, 54].
A more recent theory proposed by Thilaganathan impli-
cated abnormal cardiovascular function driving the abnor-
mal placentation that occurs within preeclampsia, and the
placental origin of preeclampsia only holds true in the case
of early onset of the disease [52, 54]. Late-onset preeclampsia
can be attributed to underlying maternal cardiovascular dys-
function which fails to meet the haemodynamic and meta-
bolic needs of the pregnancy and also results in adverse
postpartum cardiovascular outcomes in over 50% of patients,
possibly due to the fact that both preeclampsia and cardio-
vascular diseases share similar genetic and environmental
risk factors [52].
Supporting the link between placental-mediated patho-
physiology of early-onset PE, Yung et al. examined placental
samples from preterm, term, and second trimester pregnan-
cies and demonstrated that in early-onset preeclampsia, pla-
cental pathology is associated with upregulation of the
unfolded protein response (UPR) pathway and ER stress acti-
vation along with depression of the AKT pathway, reducing
cellular proliferation [55]. These authors demonstrated
molecular differences between the two phenotypes of term
and preterm preeclampsia [55].
Roberts and Hubel, amongst others, proposed a two-
stage model of preeclampsia which was later modified to six
stages by Redman et al. [53, 56]. Redman explains that stages
1 and 2 could be an early phenomenon such as preconception
tolerance of the mother towards paternal semen or short
duration between coitus and conception, leading to poor pla-
centation and affecting the health and growth of the fetus
[53]. Stage 3 begins at around 8 weeks of pregnancy where
in uncomplicated cases, trophoblastic plugs sealing the
maternal spiral arteries recede and the establishment of
uteroplacental circulation begins [53, 57]. However, in pre-
eclampsia, there is premature opening of trophoblastic plugs
with the influx of arterial blood increasing stress within the
placenta and leading to defective placentation [53]. Stage 4
of Redman’s model is characterised by decrease in placental
growth factors in cases of preeclampsia, leading to impaired
vascular remodelling of maternal spiral arteries into larger
vessels with low resistance to blood flow by trophoblast
[53, 58, 59]. Furthermore, Redman also states that with
increased placental and endothelial damage, clinical symp-
toms of preeclampsia are evident in stages 5 and 6 [53].
The development of the placenta begins with a decidual
reaction evoked by the blastocyst in the maternal endome-
trium, eventually leading to the formation of the basal plate
[60, 61]. Trophoblasts differentiate into two types: the inva-
sive extravillous cytotrophoblast (EVT) or the villous cyto-
trophoblast which later fuse to form the multinucleated
syncytiotrophoblast [61, 62]. The extravillous cytotropho-
blasts are responsible for establishment of uteroplacental
circulation and regulation of the maternal innate immune
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system [63, 64]. In uncomplicated pregnancy, extravillous
cytotrophoblasts (EVT) invade maternal spiral arteries,
veins, and lymphatic vessels of the endometrium during the
first trimester [65, 66]. EVT accumulations have also local-
ised in lymph nodes without any neoplastic changes suggest-
ing immune cell regulation by trophoblasts [65, 66].
Defective placentation results in a decrease in the angio-
genic vascular endothelial growth factor (VEGF) and placen-
tal growth factor (PLGF) and the release of deleterious
placental factors like soluble fms-like tyrosine kinase 1
(sFIt1) into the maternal circulation causing generalized
endothelial dysfunction [56, 57]. Circulating sFlt1 is abun-
dant in preeclamptic women which is attributed to vascular
resistance and increase in arterial blood pressure [67]. Recent
studies in women with fetal growth restriction (FGR) with no
symptoms of preeclampsia have provided evidence of a high
sFlt1/PLGF ratio [68, 69]. Proteinuria in preeclampsia can
also be associated with high levels of placental factors like
sFlt1, precipitating glomerular endotheliosis [70]. Altered
haemodynamic and decreased vascular flow leads to persis-
tent hypoxic-oxygenated states, resulting in high oxidative
stress within the placental tissue [55, 71–74]. Even though
elevated oxidative stress is evident in trophoblasts during
uncomplicated pregnancy, prolonged oxidative stress sup-
presses trophoblast activity, worsening the situation in preg-
nancy complications [75].
The syncytiotrophoblast is the outermost layer of the
villous trophoblast, in direct contact with maternal blood,
and syncytial debris in the form of knots or nuclear aggre-
gates can be detected in maternal circulation with increasing
gestational age [76, 77]. Constant vascular flow to the syncy-
tiotrophoblast causes rapid ageing changes and requires acti-
vation of autophagy for their removal in uncomplicated
pregnancies [8, 78, 79]. During preeclampsia, the syncytio-
trophoblast experiences accelerated ageing with upregulation
of the apoptotic cascade, necrotic breakdown with release of
necrotic debris, and increase in syncytial aggregates [77, 80].
It has been observed that the syncytiotrophoblast secretes
Senescence-Associated Beta-Galactosidase (SAβ-Gal) along
with elevation of proapoptotic p53 and CDK inhibitors, indi-
cating cessation of cell cycle and senescence [81, 82].
A recent review by Cox and Redman outlines the bio-
chemical pathway and the mechanism of ageing of placental
cells following oxidative stress [8]. They outline that the early
onset of senescence in preeclampsia can be due to excessive
ROS accumulation and oxidative/endoplasmic reticulum
(ER) stress leading to mTORC pathway (cell cycle regulator)
activation and production of Senescence-Associated Secre-
tory Phenotype (SASP) proteins which then activates the
cyclooxygenase pathway and enhances generation of proin-
flammatory cytokines and chemokines [8].
4. Cellular Senescence in Adverse
Pregnancy Outcomes
Trophoblasts mimic cancer cells by displaying invasiveness
in order to support growth of the fetus. Like neoplastic cells,
trophoblasts maintain their telomere length and Human
Telomerase Reverse Transcriptase (hTERT) level in
uncomplicated pregnancies [83, 84]. During the first trimes-
ter, the trophoblast experiences low oxygen tension or a
physiologic hypoxic state, associated with the upregulation
of HIF-1α. This low oxygen tension state is responsible for
the modelling of villous architecture and maintenance of cel-
lular integrity by preservation of telomere length and upreg-
ulation of telomerase enzymes [85, 86]. This physiologic state
is altered at the end of the first trimester when the placenta
becomes oxygenated [87]. The telomere length remains con-
stant throughout normal pregnancy, but in certain condi-
tions like fetal growth restriction and uncontrolled diabetes,
telomere length is significantly reduced [88, 89]. Telomere
changes could be associated with increased oxidative stress,
leading to DNA damage and activation of damage response
(DDR) through the p53 pathway and promoting senescence
of the trophoblast [9, 84]. In 2010, Biron-Shental et al. were
the first to report evidence of cellular senescence in pre-
eclampsia and fetal growth restriction. They demonstrated
that in preeclampsia and IUGR pregnancies, telomeres are
significantly shorter in the trophoblast with reduced expres-
sion of hTERTs with increased frequency of telomere aggre-
gates when compared to uncomplicated pregnancies [90].
These placental alterations were not present at 37-41 weeks’
gestation, indicating premature ageing of the placenta in
these pregnancy complications [90].
The placenta ages gradually, and the presence of senes-
cence markers such as p21, p16, p53, and Rb proteins
towards the term supports the ageing hypothesis of the
normal placenta [91]. Recently, a study by Nuzzo et al. shows
cell cycle changes with upregulated cyclin D1 (cell cycle
regulator) and PARP1 (expressed on DNA damage and
age-related changes) with downregulation of JunB (senes-
cence suppressor gene) in placental mesenchymal stromal
cells (PMSC) extracted from the preeclamptic placenta when
compared to the normal placenta [92]. Additionally, Sharp
et al. found an imbalance between p53 (senescence-inducing
and proapoptotic gene) and MDM2 (p53 suppressor) signal-
ling in placental proteins in the syncytiotrophoblast but not
in the cytotrophoblast in patients with early-onset pre-
eclampsia [93]. Finally, Gao et al. reported the upregulation
of p53 signalling and cell cycle arrest with activation of
proapoptotic BAX and caspase proteins in human umbilical
vein endothelial cells (HUVEC) taken from patients with
preeclampsia when compared to that from uncomplicated
pregnancy controls [94].
Activation of DDR pathways, mtDNA mutations, and
endogenous stress like ROS accumulation and redox signal-
ling can cause epigenetic modifications. Epigenetics can be
defined as physiologic changes which cannot be attributed
to the genetic code but rather modifications like phosphory-
lation, acetylation, or methylation of DNA or histone pro-
teins in the nucleus [95]. Either these changes could be an
adaptive response to persistent stimuli or they could be viru-
lent modifications leading to irreversible alterations in germ
cells [96]. The link between epigenetics, ageing, and age-
related disorders has been demonstrated in several studies.
Remodelling of chromatin may include methylation or
demethylation of histone residues at specific sites, which
can induce epigenetic changes within the cells [95, 96]. Lowe
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et al., through their research on endothelial cells collected
from the coronary artery of a 19-year-old male, discussed
that cellular ageing can be estimated precisely through
intrinsic properties of cells known as the epigenetic clock
indicated by specific DNA methylation or cytosine methyl-
ation of CpG islands, which may speed up ageing under
certain conditions [97]. Madrigano et al., through their
longitudinal study in an elderly population, showed that
gene-specific DNA methylation is strongly associated with
ageing and age-related disorders [98].
Epigenetic changes have been demonstrated within pla-
cental tissue including DNA methylation patterns, binding
ability of DNA-binding proteins or DBP (especially in the
cytochrome p450 gene), methylation patterns on imprinted
regions in H19/IGF2 genes, and methylation of histone
proteins within the human growth hormone in placental
chromatin [99]. In a recent study by Eddy et al., histone mod-
ifications were evident in the BeWo placental trophoblast
when exposed to hypoxic conditions with marked hypome-
thylation of cytosine, an epigenetic change usually evident
in age-related pathologies [100].
5. Mitochondrial Dysfunction-Associated
Ageing Changes in the Placenta
The placenta is a highly metabolic organ, requiring robust
mitochondrial activity. Even with normal mitochondrial
function, continuous changes within the extravillous tropho-
blast (EVT) and vascular remodelling lead to increased ATP
production through oxidative phosphorylation [101, 102].
Accumulation of ROS such as superoxide, nitric oxides,
and peroxynitrite results in oxidative stress during early
pregnancy [101]. ROS are signalling molecules which have
predominance over apoptotic, redox, and inflammatory-
mediated signalling pathways, respectively [103, 104]. ROS
can be generated from a number of sources including mito-
chondria (mROS), NADPH oxidases, xanthine oxidase, or
p450 enzyme [105, 106]. Reactive oxygen species (ROS) alter
macromolecules through oxidative damage to proteins
affecting gene functioning, lipid peroxidation with increased
polyunsaturated fatty acid circulation, and loss of cellular
membrane integrity [107–109]. Upregulation of ROS and
its by-product generation, lack of clearance, and redox sig-
nalling have direct links to both mitochondrial and cellular
ageing. In addition to these changes, oxidative stress activates
the Mitogen-Activated Protein Kinase (MAPK) pathway via
the Stress-Activated Protein Kinase/Jun N-Terminal Kinase
(SAPK/JNK) or p38 pathway in response to DNA damage,
which further leads to cessation of cell proliferation, and cel-
lular senescence [110].
Within the placenta, protein nitration and lipid perox-
idation have been shown to be significantly higher in tis-
sue isolated from preeclampsia patients compared with
uncomplicated pregnancy [111–113]. Lipid peroxidation
can be either enzymatic, catalysed by lipoxygenase enzymes,
or nonenzymatic in the presence of free radicals [114]. Non-
enzymatic lipid peroxidation is upregulated with ageing, and
its products are highly expressed in age-related diseases such
as atherosclerosis [115]. In 1998, Wang and Walsh described
that placental lipid peroxidation was significantly higher in
preeclampsia [111]. They established that high lipid peroxi-
dation levels are a result of escalated mitochondrial mass in
poor vascular flow to meet energy requirements in pre-
eclampsia [111].
Various systematic reviews have indicated elevated lipid
oxidation levels in preeclamptic maternal serum and plasma,
usually associated with impaired antioxidant defence when
compared with uncomplicated pregnancies [116, 117].
Low vascularization of the placenta results in a reduction
in mitochondrial size, number, and activity [118, 119]. A
recent study by Venkata et al., using the reduced uterine per-
fusion pressure (RUPP) model of preeclampsia in rats,
showed significant reduction in mitochondrial respiration,
especially in stage 3, and increased hydrogen peroxide pro-
duction when compared to control rats [118].
Nitric oxide signalling regulates cell processes such as
apoptosis, differentiation, and division [120]. Extravillous
trophoblastic activity such as migration and invasion could
be affected by two subtypes of nitric oxides, eNOS (endothe-
lial nitric oxide synthase) and iNOS (inducible nitric oxide
synthase) [120]. Nitration of proteins may either have no
effect or exhibit loss/gain of functionality. In the placenta,
peroxynitrite may alter vascular reactivity and uteroplacental
circulation in pregnancy complications such as preeclampsia
[91, 121]. Upregulation of NOS activity and peroxynitrite
accumulation in preeclampsia may result in depression of
mitochondrial activity by inhibiting the electron transport
chain and nitration of mitochondrial proteins and antioxi-
dants such as mitochondrial superoxide dismutase (MnSOD)
along with activation of trophoblastic apoptosis [122].
As shown in Figure 1, ageing is usually associated with
mitochondrial dysfunction as a direct consequence of loss
of mitochondrial dynamics and increased mitochondrial
damage [122, 123]. Mitochondria undergo continuous fis-
sion and fusion to maintain mitochondrial dynamics, failure
of which may lead to accumulation of mitochondrial debris
and deteriorate mitochondrial functioning [122, 123]. It is
believed that mitochondrial dynamics are altered in pre-
eclampsia with altered expression of mitochondrial autoph-
agy regulator genes like OPA1, SIRT3, and MNF2/1, but
limited research has been conducted to fully understand the
signalling process [124, 125]. Recently, Ausman et al.
reported that mitochondrial dynamics in preeclampsia is
inclined towards mitochondrial fission with increased phos-
phorylation of the DERP1 gene in mitochondria isolated
from preeclamptic placentas [126]. These changes were
accompanied by accumulation of ceramides which upregu-
lated BOK, a proapoptotic protein in preeclamptic placental
tissues when compared with normal placenta indicating
increased trophoblastic autophagy in preeclampsia and
IUGR [126].
Antioxidants are produced by cells to neutralise ROS
products by converting them to oxygen and hydrogen perox-
ide, which is further broken down to form water. Antioxi-
dants are also considered as antiageing agents and can be
classified into subtypes: enzymatic such as superoxide dismu-
tases (SODs), catalases, and peroxidases or nonenzymatic
such as vitamins (A, C, and E), bilirubin, and uric acid
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[127, 128]. Oxidative stress ensues when there is an imbal-
ance between the ROS by-products produced and those
scavenged by antioxidants [128, 129]. All major antioxi-
dants are localised in the placenta to reduce oxidative
stress, and their activity is dependent on the amount of
stress experienced by the cells [71]. In preeclampsia and
IUGR, antioxidant activity is attenuated when compared
to uncomplicated pregnancies, as shown in Figure 1 [127].
6. Senescence Markers in Adverse
Pregnancy Outcomes
A major obstetric challenge has been to establish biomarkers
for detection of pregnancy complications such as preeclamp-
sia and IUGR in maternal body fluids. Various markers of
mitochondrial dysfunction and oxidative stress have been
investigated as early biomarkers for pregnancy disorders, as
shown in Table 1. In 2012, Qiu et al. were the first to report
elevated mtDNA levels in the maternal peripheral blood in
preeclampsia indicating high oxidative stress and mitochon-
drial dysfunction [132]. A recent case-control study by Wil-
liamson and McCarthy and Kenny found elevated mtDNA
copy numbers in maternal plasma at 15-20 weeks’ gestation
in preeclamptic cases compared to those in uncomplicated
pregnancy controls [133, 134]. Furthermore, this study also
demonstrated significant reduction in the antioxidant mito-
chondrial superoxide dismutase (mSOD) level at 15 weeks’
gestation in women who later developed preeclampsia, thus
vindicating mitochondrial dysfunction as a pathophysiologi-
cal event in preeclampsia [134]. Another similar study by
Marschalek et al. indicated similar results with elevated
mtDNA copy numbers in maternal serum detectable in
early-onset preeclampsia [135].
Apart from mitochondrial dysfunction, inflammation
and inflammatory mediators are evident in premature ageing
of the placenta. Certain ageing-associated inflammatory
markers such as Senescence-Associated Secretory Pheno-
types (SASPs) are elevated in preeclampsia [136].
Kupferminc et al. showed that TNF-α is significantly ele-
vated in amniotic fluid and maternal plasma in severe pre-
eclampsia [137]. sST2 (soluble ST2) is a member of the
interleukin-1 family, expressed abundantly in endothelial
cells, and usually associated with age-related disorders such
as cardiac diseases [138]. In the case of elevated cell death
and necrotic signalling, the IL33/STL2 pathway is triggered
by Toll-Like Receptor-1 (TLR1) activation which leads to
upregulation of the cytokine and chemokine influx [139]. A
recent longitudinal study by Romero et al. reported signifi-
cant elevation of sST2 levels in maternal plasma in risk
patients almost 6 weeks prior to development of pre-
eclampsia [140].
MicroRNAs (miRNA) and long noncoding RNAs
(lncRNA) are noncoding RNAs that have the potential for
gene regulation [141]. miRNAs are available in bodily fluids
and are now being regularly investigated as both biomarkers
and perspective therapeutics. In the uterus, miRNAs are con-
trolled by steroidal hormones and they are responsible for
efficient placentation. Recent work by Tan et al. stated that
in adverse placental conditions like preeclampsia, long non-
coding RNA, lncRNA DLX6-AS1, is overexpressed in tro-
phoblastic cell lines, resulting in upregulation of mir-376c
which is responsible for cell cycle arrest [142].
7. Potential Therapeutics and Future
Perspectives for Adverse
Pregnancy Outcomes
Ageing is a unidirectional process which cannot be reversed;
however, research focused on reducing oxidative stress by
restoring mitochondrial fitness could be a potential therapy
for adverse pregnancy outcomes [143]. Mitochondrial fitness
is acknowledged as the key regulator for cell cycle progres-
sion and metabolism with mitochondrial interactions with
other organelles including the nucleus and endoplasmic
reticulum (ER) ensuring homeostasis of cellular dynamics
and viability. In pregnancy complications, chronic oxidative
Table 1: Senescence markers associated with placental ageing in adverse pregnancy outcomes.
Maternal plasma/serum
(1) Mitochondrial dysfunction
(2) Inflammatory marker (IL33/ST2 signalling pathway)
↑ mtDNA copy numbers
↑ sST2 level
Trophoblastic cell lines
(1) Cell cycle regulators
(2) miRNA/lncRNA
(3) DNA damage response
(4) Senescence regulators
(5) Epigenetic changes
↑ Cyclin D1
↑ Mir-376
↑ PARP1
↑ p53
↓ JunB
↓ MDM2
↑Hypomethylation of cytosine
Placenta
(1) DNA damage response
(2) Cell cycle regulators
(3) Mitochondrial dysfunction
↑ p53
↓ hTERT
↑ Telomere aggregates
↑ BAX
↑Lipid peroxidation
↑ NOS activity
↑ Peroxynitrite synthesis
↑ Phosphorylated DERP1 gene
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stress leads to mitochondrial dysfunction resulting in loss of
mitochondrial signalling stability [102]. Antioxidant supple-
ments such as vitamins C and E given during pregnancy have
not demonstrated any significant effects in reducing oxida-
tive stress.
However, continued research for more effective antioxi-
dants have shed light on a few cytoprotective agents targeting
the mitochondria.
A recent study has demonstrated that a mitochondria
targeting antioxidant, MitoTEMPO, is cytoprotective against
ROS-induced cell death [134]. When HUVEC cells were pre-
treated with MitoTEMPO before exposure to 3% plasma
from preeclampsia pregnancies, it resulted in significant
reduction in cellular superoxide production, normalization
of mitochondrial functioning, and reduction in inflamma-
tory influx [134]. Recently, another study done by Nuzzo
et al. demonstrates that mitochondrial-targeting antioxidant
MitoQ-treated pregnant rats exhibit normalized placental
volumes and rescued fetal growth restriction in hypoxic con-
ditions [144]. Furthermore, they discussed that MitoQ has
the potential to regulate the cell cycle through the MAPK
proliferation signalling pathway [144].
Finally, ergothioneine is a water soluble amino acid that
has been shown to be cytoprotective. Ergothioneine primar-
ily targets the mitochondria and can scavenge ROS, induce
cellular proliferation, and repair through upregulated antiox-
idant pathways [145]. The multitude of benefits of antioxi-
dants targeting and normalizing mitochondrial functioning
and dynamics may become potential prenatal therapeutics
for adverse pregnancy outcomes [145].
8. Conclusion
Senescence is beneficial to multicellular organisms especially
for elimination of mutations and prevention of cancers.
However, in the presence of persistent undesirable stress, this
process can accelerate unnaturally and result in serious
health complications. In adverse pregnancy outcomes such
as preeclampsia and fetal growth restriction, placental insuf-
ficiency is accompanied with aberrant signalling for prema-
ture placental senescence and apoptosis. As summarized
through Figure 1, this review has highlighted the current
knowledge on the role of placental mitochondrial dysfunc-
tion, cellular senescence, and the placental ageing axis in
adverse pregnancy outcomes.
Future research should focus on furthering our under-
standing of premature placental ageing as a pathophysiol-
ogy in pregnancy disorders and investigating novel ways
to improve outcomes such as preeclampsia and fetal
growth restriction.
Conflicts of Interest
The authors declare no conflict of interest.
Authors’ Contributions
Cathal McCarthy and Fergus P. McCarthy contributed
equally.
Acknowledgments
This project is funded by the European Union’s Horizon
2020 research and innovation programme under Marie
Skłodowska-Curie Actions Innovative Training Network
(H2020-MSCA-ITN 2017), Grant No. 765274, acronym
iPLACENTA (http://www.iplacenta.eu).
References
[1] A. L. Tranquilli, G. Dekker, L. Magee et al., “The classifica-
tion, diagnosis and management of the hypertensive disor-
ders of pregnancy: a revised statement from the ISSHP,”
Pregnancy Hypertension: An International Journal of
Women's Cardiovascular Health, vol. 4, no. 2, pp. 97–104,
2014.
[2] A. Jeyabalan, “Epidemiology of pre-eclampsia: impact of obe-
sity,” Nutrition Reviews, vol. 71, Supplement 1, pp. S18–S25,
2013.
[3] L. Duley, “The global impact of pre-eclampsia and eclamp-
sia,” Seminars in Perinatology, vol. 33, no. 3, pp. 130–137,
2009.
[4] V. Chaddha, S. Viero, B. Huppertz, and J. Kingdom, “Devel-
opmental biology of the placenta and the origins of placental
insufficiency,” Seminars in Fetal and Neonatal Medicine,
vol. 9, no. 5, pp. 357–369, 2004.
[5] F. P. McCarthy, S. Drewlo, F. A. English et al., “Evidence
implicating peroxisome proliferator-activated receptor-γ in
the pathogenesis of pre-eclampsia,” Hypertension, vol. 58,
no. 5, pp. 882–887, 2011.
[6] G. C. Kujoth, A. Hiona, T. D. Pugh et al., “Mitochondrial
DNA mutations, oxidative stress, and apoptosis in mamma-
lian aging,” Science, vol. 309, no. 5733, pp. 481–484, 2005.
[7] C. W. G. Redman and I. L. Sargent, “Placental stress and pre-
eclampsia: a revised view,” Placenta, vol. 30, pp. 38–42, 2009.
[8] L. S. Cox and C. Redman, “The role of cellular senescence in
ageing of the placenta,” Placenta, vol. 52, pp. 139–145, 2017.
[9] T. Cindrova-Davies, N. M. E. Fogarty, C. J. P. Jones,
J. Kingdom, and G. J. Burton, “Evidence of oxidative stress-
induced senescence in mature, post-mature and pathological
human placentas,” Placenta, vol. 68, pp. 15–22, 2018.
[10] P. Davy, M. Nagata, P. Bullard, N. S. Fogelson, and
R. Allsopp, “Fetal growth restriction is associated with accel-
erated telomere shortening and increased expression of cell
senescence markers in the placenta,” Placenta, vol. 30, no. 6,
pp. 539–542, 2009.
[11] T. de Lange, “How telomeres solve the end-protection prob-
lem,” Science, vol. 326, no. 5955, pp. 948–952, 2009.
[12] Y. Zhu, X. Liu, X. Ding, F. Wang, and X. Geng, “Telomere
and its role in the aging pathways: telomere shortening, cell
senescence and mitochondria dysfunction,” Biogerontology,
vol. 20, no. 1, pp. 1–16, 2019.
[13] J. W. Shay, “Role of telomeres and telomerase in aging and
cancer,” Cancer Discovery, vol. 6, no. 6, pp. 584–593, 2016.
[14] M. O’Reilly, S. A. Teichmann, and D. Rhodes, “Telomerases,”
Current Opinion in Structural Biology, vol. 9, no. 1, pp. 56–65,
1999.
[15] A. Bernadotte, V. M. Mikhelson, and I. M. Spivak, “Markers
of cellular senescence. Telomere shortening as a marker of
cellular senescence,” Aging, vol. 8, no. 1, pp. 3–11, 2016.
7Oxidative Medicine and Cellular Longevity
[16] G. Glousker and J. Lingner, “When telomerase causes telo-
mere loss,” Developmental Cell, vol. 44, no. 3, pp. 281–283,
2018.
[17] P. Margalef, P. Kotsantis, V. Borel, R. Bellelli, S. Panier, and
S. J. Boulton, “Stabilization of reversed replication forks by
telomerase drives telomere catastrophe,” Cell, vol. 172,
no. 3, pp. 439–453.e14, 2018.
[18] J. W. Shay andW. E. Wright, “Hayflick, his limit, and cellular
ageing,” Nature Reviews Molecular Cell Biology, vol. 1, no. 1,
pp. 72–76, 2000.
[19] M. Giorgio, M. Trinei, E. Migliaccio, and P. G. Pelicci,
“Hydrogen peroxide: a metabolic by-product or a common
mediator of ageing signals?,” Nature Reviews Molecular Cell
Biology, vol. 8, no. 9, pp. 722–728, 2007.
[20] M. Schieber and N. S. Chandel, “ROS function in redox sig-
naling and oxidative stress,” Current Biology, vol. 24, no. 10,
pp. R453–R462, 2014.
[21] V. N. Gladyshev, “The free radical theory of aging is dead.
Long live the damage theory!,” Antioxidants and Redox Sig-
naling, vol. 20, no. 4, pp. 727–731, 2014.
[22] P. Theurey and P. Pizzo, “The aging mitochondria,” Genes,
vol. 9, no. 1, p. 22, 2018.
[23] K. Boengler, M. Kosiol, M. Mayr, R. Schulz, and S. Rohrbach,
“Mitochondria and ageing: role in heart, skeletal muscle and
adipose tissue,” Journal of Cachexia, Sarcopenia and Muscle,
vol. 8, no. 3, pp. 349–369, 2017.
[24] G. Lenaz, “Role of mitochondria in oxidative stress and age-
ing,” Biochimica et Biophysica Acta (BBA) - Bioenergetics,
vol. 1366, no. 1-2, pp. 53–67, 1998.
[25] A. Trifunovic, A. Wredenberg, M. Falkenberg et al., “Prema-
ture ageing in mice expressing defective mitochondrial DNA
polymerase,” Nature, vol. 429, no. 6990, pp. 417–423, 2004.
[26] Y. Mikhed, A. Daiber, and S. Steven, “Mitochondrial oxida-
tive stress, mitochondrial DNA damage and their role in
age-related vascular dysfunction,” International Journal of
Molecular Sciences, vol. 16, no. 7, pp. 15918–15953, 2015.
[27] J. B. Stewart, C. Freyer, J. L. Elson, and N. G. Larsson, “Puri-
fying selection of mtDNA and its implications for under-
standing evolution and mitochondrial disease,” Nature
Reviews Genetics, vol. 9, no. 9, pp. 657–662, 2008.
[28] G. L. Norddahl, C. J. Pronk, M. Wahlestedt et al., “Accumu-
lating mitochondrial DNAmutations drive premature hema-
topoietic aging phenotypes distinct from physiological stem
cell aging,” Cell Stem Cell, vol. 8, no. 5, pp. 499–510, 2011.
[29] T. Su, D. Turnbull, and L. Greaves, “Roles of mitochondrial
DNA mutations in stem cell ageing,” Genes, vol. 9, no. 4,
p. 182, 2018.
[30] S. Abel, P. Abel zur Wiesch, B. M. Davis, and M. K. Waldor,
“Analysis of bottlenecks in experimental models of infec-
tion,” PLoS Pathogens, vol. 11, no. 6, article e1004823,
2015.
[31] Y. Kurihara, T. Kanki, Y. Aoki et al., “Mitophagy plays an
essential role in reducing mitochondrial production of reac-
tive oxygen species and mutation of mitochondrial DNA by
maintaining mitochondrial quantity and quality in yeast,”
Journal of Biological Chemistry, vol. 287, no. 5, pp. 3265–
3272, 2012.
[32] I. Kim, S. Rodriguez-Enriquez, and J. J. Lemasters, “Selec-
tive degradation of mitochondria by mitophagy,” Archives
of Biochemistry and Biophysics, vol. 462, no. 2, pp. 245–253,
2007.
[33] C. Tatone, F. Amicarelli, M. C. Carbone et al., “Cellular and
molecular aspects of ovarian follicle ageing,” Human Repro-
duction Update, vol. 14, no. 2, pp. 131–142, 2008.
[34] R. K. Lane, T. Hilsabeck, and S. L. Rea, “The role of mito-
chondrial dysfunction in age-related diseases,” Biochimica
et Biophysica Acta (BBA) - Bioenergetics, vol. 1847, no. 11,
pp. 1387–1400, 2015.
[35] A. Diot, K. Morten, and J. Poulton, “Mitophagy plays a cen-
tral role in mitochondrial ageing,” Mammalian Genome,
vol. 27, no. 7-8, pp. 381–395, 2016.
[36] L. Tilokani, S. Nagashima, V. Paupe, and J. Prudent, “Mito-
chondrial dynamics: overview of molecular mechanisms,”
Essays In Biochemistry, vol. 62, no. 3, pp. 341–360, 2018.
[37] G. Twig, A. Elorza, A. J. A. Molina et al., “Fission and selec-
tive fusion govern mitochondrial segregation and elimination
by autophagy,” The EMBO Journal, vol. 27, no. 2, pp. 433–
446, 2008.
[38] K. Palikaras, E. Lionaki, and N. Tavernarakis, “Coordination
of mitophagy and mitochondrial biogenesis during ageing in
C. elegans,” Nature, vol. 521, no. 7553, pp. 525–528, 2015.
[39] A. Hoshino, Y. Mita, Y. Okawa et al., “Cytosolic p53 inhibits
Parkin-mediated mitophagy and promotes mitochondrial
dysfunction in the mouse heart,” Nature Communications,
vol. 4, no. 1, article 2308, 2013.
[40] M. Song, K. Mihara, Y. Chen, L. Scorrano, and G. W. Dorn II,
“Mitochondrial fission and fusion factors reciprocally orches-
trate mitophagic culling in mouse hearts and cultured fibro-
blasts,” Cell Metabolism, vol. 21, no. 2, pp. 273–286, 2015.
[41] V. Jovaisaite and J. Auwerx, “The mitochondrial unfolded
protein response - synchronizing genomes,” Current Opinion
in Cell Biology, vol. 33, pp. 74–81, 2015.
[42] R. H. Houtkooper, L. Mouchiroud, D. Ryu et al., “Mitonuc-
lear protein imbalance as a conserved longevity mechanism,”
Nature, vol. 497, no. 7450, pp. 451–457, 2013.
[43] F. Urano, M. Calfon, T. Yoneda et al., “A survival pathway for
Caenorhabditis elegans with a blocked unfolded protein
response,” Journal of Cell Biology, vol. 158, no. 4, pp. 639–
646, 2002.
[44] S. Wolff and A. Dillin, “Ageing: beneficial miscommunica-
tion,” Nature, vol. 497, no. 7450, pp. 442-443, 2013.
[45] F. Licastro, G. Candore, D. Lio et al., “Innate immunity and
inflammation in ageing: a key for understanding age-related
diseases,” Immunity & Ageing, vol. 2, no. 1, p. 8, 2005.
[46] G. Pawelec, D. Goldeck, and E. Derhovanessian, “Inflamma-
tion, ageing and chronic disease,” Current Opinion in Immu-
nology, vol. 29, pp. 23–28, 2014.
[47] N. Loaiza and M. Demaria, “Cellular senescence and tumor
promotion: is aging the key?,” Biochimica et Biophysica Acta
(BBA) - Reviews on Cancer, vol. 1865, no. 2, pp. 155–167,
2016.
[48] M. E. Poynter and R. A. Daynes, “Peroxisome proliferator-
activated receptor α activation modulates cellular redox sta-
tus, represses nuclear factor-κB signaling, and reduces
inflammatory cytokine production in aging,” Journal of Bio-
logical Chemistry, vol. 273, no. 49, pp. 32833–32841, 1998.
[49] A. Freund, A. V. Orjalo, P. Y. Desprez, and J. Campisi,
“Inflammatory networks during cellular senescence: causes
and consequences,” Trends in Molecular Medicine, vol. 16,
no. 5, pp. 238–246, 2010.
[50] E. Montecino-Rodriguez, B. Berent-Maoz, and K. Dorshkind,
“Causes, consequences, and reversal of immune system
8 Oxidative Medicine and Cellular Longevity
aging,” The Journal of Clinical Investigation, vol. 123, no. 3,
pp. 958–965, 2013.
[51] B. Huppertz, “Placental origins of preeclampsia,” Hyperten-
sion, vol. 51, no. 4, pp. 970–975, 2008.
[52] B. Thilaganathan, “Pre-eclampsia is primarily a placental dis-
order,” BJOG: An International Journal of Obstetrics &
Gynaecology, vol. 124, no. 11, pp. 1763–1763, 2017.
[53] C. W. G. Redman, “The six stages of pre-eclampsia,” Preg-
nancy Hypertension: An International Journal of Women's
Cardiovascular Health, vol. 4, no. 3, p. 246, 2014.
[54] B. Thilaganathan, “Placental syndromes: getting to the heart
of the matter,” Ultrasound in Obstetrics & Gynecology,
vol. 49, no. 1, pp. 7–9, 2017.
[55] H. W. Yung, D. Atkinson, T. Campion-Smith, M. Olovsson,
D. S. Charnock-Jones, and G. J. Burton, “Differential activa-
tion of placental unfolded protein response pathways implies
heterogeneity in causation of early- and late-onset pre-
eclampsia,” The Journal of Pathology, vol. 234, no. 2,
pp. 262–276, 2014.
[56] J. M. Roberts and C. A. Hubel, “The two stage model of pre-
eclampsia: variations on the theme,” Placenta, vol. 30, pp. 32–
37, 2009.
[57] T. Tomimatsu, K. Mimura, M. Endo, K. Kumasawa, and
T. Kimura, “Pathophysiology of preeclampsia: an angiogenic
imbalance and long-lasting systemic vascular dysfunction,”
Hypertension Research, vol. 40, no. 4, pp. 305–310, 2017.
[58] F. Reister, H. G. Frank, J. C. P. Kingdom et al., “Macrophage-
induced apoptosis limits endovascular trophoblast invasion
in the uterine wall of preeclamptic women,” Laboratory
Investigation, vol. 81, no. 8, pp. 1143–1152, 2001.
[59] F. Colucci, “The role of KIR and HLA interactions in preg-
nancy complications,” Immunogenetics, vol. 69, no. 8-9,
pp. 557–565, 2017.
[60] B. Pansky, “Chapter 41, Placental physiology,” Review of
Medical Embyology, 1982.
[61] J. S. Lowe and P. G. Anderson, “Chapter 17 - female repro-
ductive system,” in Stevens & Lowe's Human Histology
(Fourth Edition), J. S. Lowe and P. G. Anderson, Eds.,
pp. 337–362, Mosby, Philadelphia, 2015.
[62] A. Tarrade, R. Lai Kuen, A. Malassiné et al., “Characterization
of human villous and extravillous trophoblasts isolated from
first trimester placenta,” Laboratory Investigation, vol. 81,
no. 9, pp. 1199–1211, 2001.
[63] G. J. Burton and A. L. Fowden, “The placenta: a multifaceted,
transient organ,” Philosophical Transactions of the Royal Soci-
ety B: Biological Sciences, vol. 370, no. 1663, article 20140066,
2015.
[64] G. J. Burton and E. Jauniaux, “What is the placenta?,” Amer-
ican Journal of Obstetrics and Gynecology, vol. 213, no. 4, pp. -
S6.e1–S6.e4, 2015.
[65] D. Goldman-Wohl and S. Yagel, “Regulation of trophoblast
invasion: from normal implantation to pre-eclampsia,”
Molecular and Cellular Endocrinology, vol. 187, no. 1-2,
pp. 233–238, 2002.
[66] K. Windsperger, S. Dekan, S. Pils et al., “Extravillous tropho-
blast invasion of venous as well as lymphatic vessels is altered
in idiopathic, recurrent, spontaneous abortions,” Human
Reproduction, vol. 32, no. 6, pp. 1208–1217, 2017.
[67] K. Koga, Y. Osuga, O. Yoshino et al., “Elevated serum soluble
vascular endothelial growth factor receptor 1 (sVEGFR-1)
levels in women with pre-eclampsia,” The Journal of Clinical
Endocrinology & Metabolism, vol. 88, no. 5, pp. 2348–2351,
2003.
[68] S. Shinohara, Y. Uchida, M. Kasai, and R. Sunami, “Associa-
tion between the high soluble fms-like tyrosine kinase-1 to
placental growth factor ratio and adverse outcomes in asymp-
tomatic women with early-onset fetal growth restriction,”
Hypertension in Pregnancy, vol. 36, no. 3, pp. 269–275, 2017.
[69] I. Herraiz, M. S. Quezada, J. Rodriguez-Calvo, E. Gómez-
Montes, C. Villalaín, and A. Galindo, “Longitudinal change
of sFlt-1/PlGF ratio in singleton pregnancy with early-onset
fetal growth restriction,” Ultrasound in Obstetrics & Gynecol-
ogy, vol. 52, no. 5, pp. 631–638, 2018.
[70] I. M. Craici, S. J. Wagner, T. L. Weissgerber, J. P. Grande, and
V. D. Garovic, “Advances in the pathophysiology of pre-
eclampsia and related podocyte injury,”Kidney International,
vol. 86, no. 2, pp. 275–285, 2014.
[71] L. Myatt and X. Cui, “Oxidative stress in the placenta,”Histo-
chemistry and Cell Biology, vol. 122, no. 4, pp. 369–382, 2004.
[72] C. W. G. Redman and I. L. Sargent, “Placental debris, oxida-
tive stress and pre-eclampsia,” Placenta, vol. 21, no. 7,
pp. 597–602, 2000.
[73] O. Genbacev, Y. Zhou, J. W. Ludlow, and S. J. Fisher, “Regu-
lation of human placental development by oxygen tension,”
Science, vol. 277, no. 5332, pp. 1669–1672, 1997.
[74] C. H. Damsky, M. L. Fitzgerald, and S. J. Fisher, “Distribution
patterns of extracellular matrix components and adhesion
receptors are intricately modulated during first trimester
cytotrophoblast differentiation along the invasive pathway,
in vivo,” Journal of Clinical Investigation, vol. 89, no. 1,
pp. 210–222, 1992.
[75] M. H. Schoots, S. J. Gordijn, S. A. Scherjon, H. van Goor, and
J. L. Hillebrands, “Oxidative stress in placental pathology,”
Placenta, vol. 69, pp. 153–161, 2018.
[76] S. Guller, “Role of the syncytium in placenta-mediated com-
plications of preeclampsia,” Thrombosis Research, vol. 124,
no. 4, pp. 389–392, 2009.
[77] C. S. Roland, J. Hu, C. E. Ren et al., “Morphological changes
of placental syncytium and their implications for the patho-
genesis of preeclampsia,” Cellular and Molecular Life Sci-
ences, vol. 73, no. 2, pp. 365–376, 2016.
[78] S. J. Coleman, L. Gerza, C. J. P. Jones, C. P. Sibley, J. D. Aplin,
and A. E. P. Heazell, “Syncytial nuclear aggregates in normal
placenta show increased nuclear condensation, but apoptosis
and cytoskeletal redistribution are uncommon,” Placenta,
vol. 34, no. 5, pp. 449–455, 2013.
[79] C. P. Chen, K. G.Wang, C. Y. Chen, C. Yu, H. C. Chuang, and
H. Chen, “Altered placental syncytin and its receptor ASCT2
expression in placental development and pre-eclampsia,”
BJOG: An International Journal of Obstetrics & Gynaecology,
vol. 113, no. 2, pp. 152–158, 2006.
[80] H. Soma, K. Yoshida, T. Mukaida, and Y. Tabuchi, “Morpho-
logic changes in the hypertensive placenta,” Contributions to
Gynecology and Obstetrics, vol. 9, pp. 58–75, 1982.
[81] S. Roberge, K. Nicolaides, S. Demers, J. Hyett, N. Chaillet, and
E. Bujold, “The role of aspirin dose on the prevention of pre-
eclampsia and fetal growth restriction: systematic review and
meta-analysis,” American Journal of Obstetrics and Gynecol-
ogy, vol. 216, no. 2, pp. 110–120.e6, 2017.
[82] A. N. Sharp, A. E. P. Heazell, D. Baczyk et al., “Preeclampsia
is associated with alterations in the p53-pathway in villous
trophoblast,” PLoS One, vol. 9, no. 1, article e87621, 2014.
9Oxidative Medicine and Cellular Longevity
[83] S. E. Hallows, T. R. H. Regnault, and D. H. Betts, “The long
and short of it: the role of telomeres in fetal origins of adult
disease,” Journal of Pregnancy, vol. 2012, Article ID 638476,
8 pages, 2012.
[84] T. Biron-Shental, D. Sadeh-Mestechkin, and A. Amiel, “Telo-
mere homeostasis in IUGR placentas - a review,” Placenta,
vol. 39, pp. 21–23, 2016.
[85] F. Ietta, Y. Wu, J. Winter et al., “Dynamic HIF1A regulation
during human placental development,” Biology of Reproduc-
tion, vol. 75, no. 1, pp. 112–121, 2006.
[86] H. Nishi, T. Nakada, S. Kyo, M. Inoue, J. W. Shay, and
K. Isaka, “Hypoxia-inducible factor 1 mediates upregulation
of telomerase (hTERT),” Molecular and Cellular Biology,
vol. 24, no. 13, pp. 6076–6083, 2004.
[87] K. Vrijens, M. Tsamou, N. Madhloum, W. Gyselaers, and
T. S. Nawrot, “Placental hypoxia-regulating network in rela-
tion to birth weight and ponderal index: the ENVIRONAGE
Birth Cohort Study,” Journal of Translational Medicine,
vol. 16, no. 1, p. 2, 2018.
[88] T. Biron-Shental, R. Sukenik-Halevy, H. Naboani,
M. Liberman, R. Kats, and A. Amiel, “Telomeres are shorter
in placentas from pregnancies with uncontrolled diabetes,”
Placenta, vol. 36, no. 2, pp. 199–203, 2015.
[89] J. Toutain, M. Prochazkova-Carlotti, D. Cappellen et al.,
“Reduced placental telomere length during pregnancies com-
plicated by intrauterine growth restriction,” PLoS One, vol. 8,
no. 1, article e54013, 2013.
[90] T. Biron-Shental, R. Sukenik-Halevy, Y. Sharon et al., “Short
telomeres may play a role in placental dysfunction in pre-
eclampsia and intrauterine growth restriction,” American
Journal of Obstetrics and Gynecology, vol. 202, no. 4,
pp. 381.e1–381.e7, 2010.
[91] A. M. Roggensack, Y. Zhang, and S. T. Davidge, “Evidence
for peroxynitrite formation in the vasculature of women
with pre-eclampsia,” Hypertension, vol. 33, no. 1, pp. 83–89,
1999.
[92] A. M. Nuzzo, D. Giuffrida, B. Masturzo et al., “Altered
expression of G1/S phase cell cycle regulators in placental
mesenchymal stromal cells derived from preeclamptic preg-
nancies with fetal-placental compromise,” Cell Cycle,
vol. 16, no. 2, pp. 200–212, 2017.
[93] A. N. Sharp, A. E. P. Heazell, D. Baczyk et al., “Pre-eclamp-
sia is associated with alterations in the p53-pathway in
villous trophoblast,” PLoS One, vol. 9, no. 1, article
e87621, 2014.
[94] Q. Gao, X. Zhu, J. Chen, C. Mao, L. Zhang, and Z. Xu,
“Upregulation of P53 promoted G1 arrest and apoptosis in
human umbilical cord vein endothelial cells from pre-
eclampsia,” Journal of Hypertension, vol. 34, no. 7,
pp. 1380–1388, 2016.
[95] L. Mirbahai and J. K. Chipman, “Epigenetic memory of
environmental organisms: a reflection of lifetime stressor
exposures,” Mutation Research/Genetic Toxicology and
Environmental Mutagenesis, vol. 764-765, pp. 10–17, 2014.
[96] K. Leavey, S. L. Wilson, S. A. Bainbridge, W. P. Robinson, and
B. J. Cox, “Epigenetic regulation of placental gene expression
in transcriptional subtypes of pre-eclampsia,” Clinical Epige-
netics, vol. 10, no. 1, p. 28, 2018.
[97] D. Lowe, S. Horvath, and K. Raj, “Epigenetic clock analyses of
cellular senescence and ageing,” Oncotarget, vol. 7, no. 8,
pp. 8524–8531, 2016.
[98] J. Madrigano, A. A. Baccarelli, M. A. Mittleman et al., “Aging
and epigenetics: longitudinal changes in gene-specific DNA
methylation,” Epigenetics, vol. 7, no. 1, pp. 63–70, 2012.
[99] M. A. Maccani and C. J. Marsit, “Review article: epigenetics in
the placenta,” American Journal of Reproductive Immunol-
ogy, vol. 62, no. 2, pp. 78–89, 2009.
[100] A. C. Eddy, H. Chapman, and E. M. George, “Acute hypoxia
and chronic ischemia induce differential total changes in pla-
cental epigenetic modifications,” Reproductive Sciences, no. -
article 1933719118799193, 2018.
[101] G. J. Burton, C. P. Sibley, E. R. M. Jauniaux, S. G. Gabbe,
J. R. Niebyl, J. L. Simpson, M. B. Landon, H. L. Galan,
D. A. Driscoll, V. Berghella, and W. A. Grobman, Eds.,
“Chapter 1: placental anatomy and physiology,” in Obstetrics:
Normal and Problem Pregnancies, Elsevier, 7th edition, 2016.
[102] G. J. Burton, H. W. Yung, and A. J. Murray, “Mitochondrial-
endoplasmic reticulum interactions in the trophoblast: stress
and senescence,” Placenta, vol. 52, pp. 146–155, 2017.
[103] J. Zhang, X. Wang, V. Vikash et al., “ROS and ROS-mediated
cellular signaling,” Oxidative Medicine and Cellular Longev-
ity, vol. 2016, Article ID 4350965, 18 pages, 2016.
[104] T. Finkel, “Signal transduction by reactive oxygen species,”
Journal of Cell Biology, vol. 194, no. 1, pp. 7–15, 2011.
[105] C. M. McCarthy and L. C. Kenny, “Mitochondrial [dys]func-
tion; culprit in preeclampsia?,” Clinical Science, vol. 130,
no. 14, pp. 1179–1184, 2016.
[106] P. Jezek and L. Hlavata, “Mitochondria in homeostasis of
reactive oxygen species in cell, tissues, and organism,” The
International Journal of Biochemistry & Cell Biology, vol. 37,
no. 12, pp. 2478–2503, 2005.
[107] T. Finkel and N. J. Holbrook, “Oxidants, oxidative stress and
the biology of ageing,” Nature, vol. 408, no. 6809, pp. 239–
247, 2000.
[108] M. Ott, V. Gogvadze, S. Orrenius, and B. Zhivotovsky, “Mito-
chondria, oxidative stress and cell death,” Apoptosis, vol. 12,
no. 5, pp. 913–922, 2007.
[109] G. J. Burton and E. Jauniaux, “Oxidative stress,” Best Practice
& Research Clinical Obstetrics & Gynaecology, vol. 25, no. 3,
pp. 287–299, 2011.
[110] X. Luo, Z. W. Yao, H. B. Qi et al., “Gadd45α as an upstream
signaling molecule of p38 MAPK triggers oxidative stress-
induced sFlt-1 and sEng upregulation in preeclampsia,” Cell
and Tissue Research, vol. 344, no. 3, pp. 551–565, 2011.
[111] Y. Wang and S. W. Walsh, “Placental mitochondria as a
source of oxidative stress in pre-eclampsia,” Placenta,
vol. 19, no. 8, pp. 581–586, 1998.
[112] V. Toescu, S. L. Nuttall, U. Martin, M. J. Kendall, and
F. Dunne, “Oxidative stress and normal pregnancy,” Clinical
Endocrinology, vol. 57, no. 5, pp. 609–613, 2002.
[113] A. Fujimaki, K. Watanabe, T. Mori, C. Kimura, K. Shinohara,
and A. Wakatsuki, “Placental oxidative DNA damage and its
repair in preeclamptic women with fetal growth restriction,”
Placenta, vol. 32, no. 5, pp. 367–372, 2011.
[114] M. Repetto, J. Semprine, and A. Boveris, “Lipid peroxidation:
chemical mechanism, biological implications and analytical
determination,” in Lipid Peroxidation, IntechOpen, 2012.
[115] G. Spiteller, “Lipid peroxidation in aging and age-dependent
diseases,” Experimental Gerontology, vol. 36, no. 9, pp. 1425–
1457, 2001.
[116] S. Gupta, N. Aziz, L. Sekhon et al., “Lipid peroxidation and
antioxidant status in preeclampsia: a systematic review,”
10 Oxidative Medicine and Cellular Longevity
Obstetrical & Gynecological Survey, vol. 64, no. 11, pp. 750–
759, 2009.
[117] E. Llurba, E. Gratacós, P. Martıń-Gallán, L. Cabero, and
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